The generic drug company Ranbaxy USA, a unit of India's largest pharmaceutical company, is paying a fine of $500 million for selling adulterated drugs and making false statements about manufacturing practices to FDA regulators. In a statement, Ranbaxy said it fully cooperated with authorities and that the fines reflected actions from past years.

Related Summaries